
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
HER2-mutant non–small cell lung cancer (NSCLC) presents a significant unmet need in oncology, particularly concerning targeted therapeutic options. While advancements have been made in other oncogenic drivers like EGFR, ALK, and ROS1, the landscape for …